My take is this is seperate to the SubB2M program. EXO-NET is a platform technology used for isolating the relevant exosomes from the sample in question i.e., blood sample from a potential / suspected ovarian cancer patient. The assay UQ will be develop will to detect the relevant exosome marker in question.
Please also note that releasing news of signing a CRO for the SubB2M program is also no guarantee. Will they tech transfer a test developed in the iNOVIQ lab (ELISA / IHC) and if so, optimisation, validation and test readiness under a NATA / CAP accredited lab will need to be completed in roughly 12 - 18 months if we are to see an LDT launch in 2023. Importantly, are they manufacturing a research grade SubB2M product in the meantime in order to provide to the CRO to test in the developed assay?
My take is this is seperate to the SubB2M program. EXO-NET is a...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
-0.015(2.61%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 58.0¢ | 56.0¢ | $41.63K | 72.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18565 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 57.5¢ | 4488 | 1 |
View Market Depth
| Last trade - 15.51pm 24/06/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |